Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Real-world data now suggest that GLP-1s may reduce HS morbidity
Cycle Length: Short cycles of 4 to 6 weeks are common to avoid receptor desensitization and long-term side effects
The Data: Phase 3 vs Phase 2 Note: these are cross-phase comparisons retatrutide's figures come from completed Phase 3 trials, zenagamtide's from Phase 2
Most members pay less than $30/visit
US$ 28.85
US$ 23.83
US$ 21.34
US$ 21.87
